Actively Recruiting
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Led by Peking University First Hospital · Updated on 2025-09-18
200
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal diseases that can come and go over a person's lifetime and currently have no cure. Researchers are studying how to predict how patients will respond to biologic treatments, which are expensive and do not work for 30-50% of patients. The goal is to develop a reliable model using clinical data and biomarkers to guide personalized treatment decisions for IBD patients. The study will collect detailed clinical information from IBD patients at Peking University First Hospital who are treated with different biologics, including anti-cytokine antibodies and anti-integrin antibodies. Patients will be grouped based on the biologic type they receive. Researchers will analyze the data using statistical and machine learning methods to create and compare models that predict treatment response and then develop a user-friendly clinical tool based on the best model. Participants will provide clinical data including baseline characteristics, biomarker levels, and treatment responses. The main outcome measured is disease activity up to 8 weeks after biologic treatment. This observational study will help improve treatment outcomes by supporting clinical decisions and potentially reducing healthcare costs. The study starts in August 2025 and is sponsored by Peking University First Hospital.
CONDITIONS
Brief Title
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients clinically diagnosed with inflammatory bowel disease at the hospital
- Disease activity is currently in the active stage
- Receiving biologic treatment after diagnosis
- Have clinical evaluation data following biologic treatment
You will not qualify if you...
- Patients diagnosed with inflammatory bowel disease who have not received biologic treatment after diagnosis
- Patients with inflammatory bowel disease and other autoimmune diseases requiring biologics
- Patients with blood diseases or other systemic chronic inflammatory diseases affecting the intestine
- Patients with serious complications such as malignant tumors or gastrointestinal perforation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks
Participants who undergo routine care with biologic treatments for inflammatory bowel disease are observed to collect clinical evaluation data.
Periodic visits during treatment
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, China
Actively Recruiting
Research Team
R
Raphael Hong
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here